SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation syndrome (ARS ...
CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced a partnership valued at up to $119 million ...
Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's ...
Company Presented Entolimod™ from its TLR5 Platform to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs SAN ANTONIO, April 28, 2026 /PRNewswire/ -- ...
(RTTNews) - Pluri Inc. (PLUR), a biotechnology company specializing in cell-based solutions, announced on Monday that it is assessing its readiness to initiate mass production of PLX-R18, a potential ...
FREMONT, CA / ACCESS Newswire / November 18, 2025 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage therapeutics company, today announced it has secured an exclusive Techwatch meeting with the ...
The FDA granted an orphan drug designation for the novel drug, NT-17, to treat people with acute radiation syndrome. The Food and Drug Administration (FDA) has granted Orphan Drug Designation for the ...
Radiation exposure in medical treatment, industry, space and emergencies can trigger life-threatening acute radiation syndrome (ARS), marked by hematopoietic failure and organ damage. Most current ...
Redhill Biopharma Ltd.'s opaganib hydrochloride (ABC-294640) has been selected by the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results